• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

    13.55 +0.24 (+1.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Phathom Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Leadership Succession
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.